title: US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.
abstract: Several disease-modifying agents (DMAs) are approved for the treatment of multiple sclerosis, including three interferon (IFN)-beta products, glatiramer acetate and mitoxantrone. This article reviews the adverse event profiles of these DMAs based on the pivotal phase III trials, and provides practical guidelines for managing adverse effects. In general, the most common adverse events associated with IFN beta therapy are flu-like symptoms, including fever, chills and myalgias, and headache. The flu-like symptoms typically resolve within 24 hours and may be mitigated by over-the-counter anti-inflammatory agents. Adverse events related to glatiramer acetate therapy include injection-site reactions and a systemic reaction consisting of flushing, chest tightness, palpitation, anxiety or dyspnoea. The systemic reaction is transient (30 seconds to 30 minutes) and self-limited. Mitoxantrone may cause nausea, vomiting, alopecia, amenorrhoea and myelosuppression; isolated cases of acute leukaemia and dose-related cardiotoxicity have been reported in the literature. Longer-term tolerability data on mitoxantrone as a treatment for multiple sclerosis are needed. It is important for physicians to counsel patients on DMA-related adverse effects, most of which are transient and of mild-to-moderate severity. Various strategies that can be employed to prevent or manage these adverse effects and lessen their impact on the patient are discussed.
authors.affiliation: Department of Neurology, University of Pennsylvania Hospital, Philadelphia, Pennsylvania 19104, USA. galetta@mail.med.upenn.edu
authors.forename: Steven L
authors.initials: SL
authors.lastname: Galetta
authors.forename: Clyde
authors.initials: C
authors.lastname: Markowitz
mesh_terms: D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
references.citation: Lancet. 2002 Dec 21-28;360(9350):2018-25
references.pmid: 12504397
references.citation: Can J Neurol Sci. 2004 Feb;31(1):58-63
references.pmid: 15038472
references.citation: Mult Scler. 2002 Oct;8(5):441-5
references.pmid: 12356214
references.citation: Ann Neurol. 1996 Mar;39(3):285-94
references.pmid: 8602746
references.citation: Lancet. 1998 Nov 7;352(9139):1498-504
references.pmid: 9820297
references.citation: Neurology. 1999 Nov 10;53(8):1622-7
references.pmid: 10563602
references.citation: Mult Scler. 2003 Mar;9(2):213-4
references.pmid: 12708818
references.citation: Drugs Aging. 1997 Jun;10(6):473-85
references.pmid: 9205852
references.citation: Neurology. 2001 May 22;56(10):1416
references.pmid: 11376205
references.citation: Arch Dermatol. 1999 Oct;135(10):1277-8
references.pmid: 10522686
references.citation: N Engl J Med. 2000 Sep 28;343(13):898-904
references.pmid: 11006365
references.citation: Neurology. 2002 Sep 24;59(6):954-5
references.pmid: 12297591
references.citation: Neurology. 2002 Nov 26;59(10):1496-506
references.pmid: 12451188
references.citation: Arch Neurol. 1997 May;54(5):531-3
references.pmid: 9152109
references.citation: Mult Scler. 1996 Jul;1(6):329-32
references.pmid: 9345411
references.citation: Neurology. 1993 Apr;43(4):655-61
references.pmid: 8469318
references.citation: Neurology. 2001 Jun 26;56(12):1628-36
references.pmid: 11425926
references.citation: J Behav Med. 1997 Oct;20(5):433-45
references.pmid: 9415854
references.citation: Neurology. 2002 Nov 26;59(10 ):1507-17
references.pmid: 12451189
references.citation: Neurology. 2002 Sep 10;59(5):679-87
references.pmid: 12221157
references.citation: Neurology. 2001 Jun 12;56(11):1496-504
references.pmid: 11402106
references.citation: Drug Saf. 2003;26(11):815-27
references.pmid: 12908850
references.citation: Neurology. 1998 Jun;50(6):1910-2
references.pmid: 9633761
references.citation: Drugs. 1991 Mar;41(3):400-49
references.pmid: 1711446
references.citation: Lancet. 1998 Nov 7;352(9139):1491-7
references.pmid: 9820296
references.citation: J Neurol. 2003 Feb;250(2):241-2
references.pmid: 12622093
references.citation: Leukemia. 1998 Mar;12(3):441-2
references.pmid: 9529141
references.citation: Cutis. 2001 Oct;68(4):287-8
references.pmid: 11710450
references.citation: Neurology. 1996 Jan;46(1):12-8
references.pmid: 8559358
references.citation: J Neurol Neurosurg Psychiatry. 2003 Dec;74(12):1689-92
references.pmid: 14638892
references.citation: Neurology. 1998 Feb;50(2):570-1
references.pmid: 9484407
references.citation: Arch Intern Med. 2002 Oct 28;162(19):2161-9
references.pmid: 12390057
references.citation: J Neurol. 1997 Mar;244(3):153-9
references.pmid: 9050955
references.citation: J Neurol. 2000 Mar;247(3):220-1
references.pmid: 10787120
references.citation: Clin Ther. 1997 Sep-Oct;19(5):883-93
references.pmid: 9385477
references.citation: Neurology. 1995 Jul;45(7):1268-76
references.pmid: 7617181
references.citation: Lancet. 2002 Apr 27;359(9316):1453-60
references.pmid: 11988242
references.citation: Drug Saf. 2000 Feb;22(2):149-59
references.pmid: 10672896
references.citation: Neurology. 2002 Apr 23;58(8 Suppl 4):S10-22
references.pmid: 11971122
references.citation: Neurology. 1995 Jul;45(7):1277-85
references.pmid: 7617182
references.citation: Mult Scler. 2003 Feb;9(1):59-62
references.pmid: 12617270
references.citation: Am J Gastroenterol. 2002 Mar;97(3):767-8
references.pmid: 11922585
references.citation: Neurologist. 2002 Jul;8(4):227-36
references.pmid: 12803682
references.citation: J Neurol. 1996 Apr;243(4 Suppl 1):S23-6
references.pmid: 8965117
references.citation: Leukemia. 2003 May;17(5):985-6
references.pmid: 12750718
references.citation: Neurol Sci. 2003 Dec;24(5):361-4
references.pmid: 14716534
references.citation: Neurology. 2004 Feb 24;62(4):628-31
references.pmid: 14981183